Loading...

CNSP CNS PHARMACEUTICALS INC Operational Disruptions 8-K Filing

CNS

CNSP

CNS PHARMACEUTICALS INC

(CNSP)

2023 8-K

Show Summary

Summary

Reverse Stock Split

Investor Meetings

Equity Offerings

Public Offering

Clinical Trial Update

Financial Update

Equity Offering

Earnings Report

Clinical Trial Update

Clinical Trial Update

Financial Update

Quantitative Data

Filing Letter with Quantita...

US FDA Inspection

Filing with Quantitative Data

Securities Purchase Agreements

Securities Purchase Agreements

Filing with Quantitative Data

Securities Purchase Agreements

Quantitative Data

Clinical Trial Update

Clinical Trial Update

Update on Berubicin Phase 2...

Public Offering

Update on Drug Candidate

Clinical Trial Update

Clinical Trial Update

Warrant Exercise

Other Special Situation

Management Changes

Clinical Trial Update

Clinical Trial Update

Earnings Reports

External Links:

CNS Pharmaceuticals, Inc. filed a letter providing an update on the progress of its drug candidate Berubicin, including positive results from a Phase 2 clinical trial in patients with glioblastoma multiforme (GBM).

AI Assistant

CNS PHARMACEUTICALS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.